141 related articles for article (PubMed ID: 27558262)
1. Preclinical evaluation of [
Vangestel C; Thomae D; Van Soom J; Ides J; Wyffels L; Pauwels P; Stroobants S; Van der Veken P; Magdolen V; Joossens J; Augustyns K; Staelens S
Contrast Media Mol Imaging; 2016 Nov; 11(6):448-458. PubMed ID: 27558262
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Ides J; Thomae D; Wyffels L; Vangestel C; Messagie J; Joossens J; Lardon F; Van der Veken P; Augustyns K; Stroobants S; Staelens S
Nucl Med Biol; 2014 Jul; 41(6):477-87. PubMed ID: 24768145
[TBL] [Abstract][Full Text] [Related]
3. Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of plasminogen activator inhibitor type 2 (PAI-2) forms.
Ranson M; Berghofer P; Vine KL; Greguric I; Shepherd R; Katsifis A
Nucl Med Biol; 2012 Aug; 39(6):833-9. PubMed ID: 22817872
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
Liu D; Overbey D; Watkinson L; Giblin MF
Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
[TBL] [Abstract][Full Text] [Related]
6. Imaging active urokinase plasminogen activator in prostate cancer.
LeBeau AM; Sevillano N; Markham K; Winter MB; Murphy ST; Hostetter DR; West J; Lowman H; Craik CS; VanBrocklin HF
Cancer Res; 2015 Apr; 75(7):1225-35. PubMed ID: 25672980
[TBL] [Abstract][Full Text] [Related]
7. Utilizing the Multiradionuclide Resolving Power of SPECT and Dual Radiolabeled Single Molecules to Assess Treatment Response of Tumors.
Xu B; Shokeen M; Sudlow GP; Harpstrite SE; Liang K; Cheney PP; Edwards WB; Sharma V; Laforest R; Akers WJ; Achilefu S
Mol Imaging Biol; 2015 Oct; 17(5):671-9. PubMed ID: 25790774
[TBL] [Abstract][Full Text] [Related]
8. ¹¹¹In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages.
Terry SY; Boerman OC; Gerrits D; Franssen GM; Metselaar JM; Lehmann S; Oyen WJ; Gerdes CA; Abiraj K
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1430-8. PubMed ID: 26012900
[TBL] [Abstract][Full Text] [Related]
9. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
10. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
12. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours.
Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B
Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
[TBL] [Abstract][Full Text] [Related]
15. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
16. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
17. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
[TBL] [Abstract][Full Text] [Related]
18. Investigations of (99m)Tc-labeled glucarate as a SPECT radiotracer for non-small cell lung cancer (NSCLC) and potential tumor uptake mechanism.
Meng L; Xiu Y; Li Y; Xu X; Li S; Li X; Pak KY; Shi H; Cheng D
Nucl Med Biol; 2015 Jul; 42(7):608-13. PubMed ID: 25890861
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
20. In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor.
Krüwel T; Nevoltris D; Bode J; Dullin C; Baty D; Chames P; Alves F
Sci Rep; 2016 Feb; 6():21834. PubMed ID: 26912069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
